While broad evidences confirm the safety of glucose-lowering agents from these classes except saxagliptin, several clinical trials strongly indicate drug-specific, beneficial effects of SGLT2i and GLP1-RA on cardiovascular outcome in T2D patients with high cardiovascular risk. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.